Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frankel, A. E.
Right arrow Articles by Kreitman, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frankel, A. E.
Right arrow Articles by Kreitman, R. J.
Clinical Cancer Research Vol. 8, 1004-1013, May 2002
© 2002 American Association for Cancer Research

Clinical Trials

Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia1

Arthur E. Frankel2, Bayard L. Powell, Philip D. Hall, L. Douglas Case and Robert J. Kreitman

Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina 27157 [A. E. F., B. L. P., L. D. C.]; Medical University of South Carolina, Charleston, South Carolina 29425 [P. D. H.]; and Laboratory of Molecular Biology, National Cancer Institute, Bethesda, Maryland 20892 [R. J. K.]


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Purpose: Patients with relapsed or refractory acute myeloid leukemia have a poor prognosis. We tested the safety and efficacy of a diphtheria fusion protein [diphtheria toxin (DT)388 granulocyte-macrophage colony-stimulating factor (GMCSF)] directed against the GMCSF receptor that is strongly expressed by leukemic blasts.

Experimental Design: DT388GMCSF fusion protein containing the catalytic and translocation domains of DT388 fused to human GMCSF was administered in an interpatient dose escalation trial by 15 min i.v. infusion daily for up to 5 days.

Results: The maximal tolerated dose was 4 µg/kg/day. The dose-limiting toxicity was liver injury and occurred at the 4.5–5-µg/kg/day dose level. Among nine treated patients at these doses, one patient developed liver failure, and one patient had transient hepatic encephalopathy. There was a positive correlation between peak serum DT388GMCSF levels and serum aspartate aminotransferase (P = 0.0002). DT388GMCSF did not damage hepatic cell lines in vitro; however, DT388GMCSF binds macrophages and induces cytokine release in vitro. Among the treated patients, we observed an early elevation in serum levels of interleukin (IL)-18 and a later rise in IL-8 but no significant changes in IL-1ß, IL-6, IFN{gamma}, macrophage inflammatory protein-1{alpha}, tumor necrosis factor {alpha} or IL-12. The IL-18 elevations occurred before elevations of liver enzymes and correlated with peak aspartate aminotransferase levels (P = 0.005). Of the 31 patients who were resistant to chemotherapy, 1 had a complete remission and 2 had partial remissions; all 3 of these patients were treated at or above the maximal tolerated dose, all 3 responding patients had baseline marrow blast percentage of <30%, whereas only 6 of the nonresponding 28 patients had less than 30% marrow blasts. Five of these six patients were treated with subtherapeutic doses. Eight (42%) of 19 patient courses at <4 µg/kg/day and 8 (40%) of 20 patient courses at 4–5 µg/kg/day showed marrow blast reductions at day 12. Patients with higher pretreatment anti-DT388GMCSF levels had significantly lower peak DT388GMCSF levels (P = 0.0001).

Conclusions: DT388GMCSF can produce complete and partial remissions in patients with chemotherapy-resistant acute myeloid leukemia, but methods to prevent liver injury are needed before more widespread application of this novel agent.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
AML3 is the most common acute leukemia in adults with 10,000 new cases/year in the United States (1) . With combination induction and consolidation chemotherapy using cytarabine and topoisomerase II inhibitors such as daunorubicin and etoposide, complete remission rates of about 70% have been achieved (2) . However, most patients ultimately relapse and die from the disease or complications of treatment. The prognosis is dismal for patients with relapsed or refractory AML. Except for the minority of patients who undergo allogeneic bone marrow transplants or have initial complete remissions of >12 months, patients receive salvage therapy similar to that used in their induction/consolidation and have a median survival of weeks to months (3) . Two-year survival in this subgroup of relapsed and refractory patients is rare.

Chemotherapy-resistant blasts contribute to treatment failures in AML patients (4) . These blasts are resistant to multiple drugs and often show altered expression of one or more resistance proteins that influence drug efflux, drug metabolism, substrate levels, or cell death regulation (5 , 6) . Because most of the multidrug resistance phenotypes target low-molecular-weight inhibitors of DNA synthesis or cell proliferation, we searched for an agent that could induce leukemic cell death by mechanisms other than damage to DNA or cell division.

One novel class of AML therapeutics are DT fusion proteins consisting of the catalytic and translocation domains of DT genetically fused to AML blast selective ligands (7) . The ligand delivers the protein to blast cell surface receptors. After receptor-mediated endocytosis, the fusion protein reaches the early endosomes, to which it is cleaved by furin and, in the acidic environment, inserts into the vesicle membrane and facilitates the escape of the DT-A fragment to the cytosol. In the cytosol, the A fragment ADP-ribosylates elongation factor 2, which leads to the inactivation of protein synthesis and cell death.

Because GMCSF receptors are expressed on the majority of myeloid leukemias but are poorly expressed on early normal hematopoietic stem cells, we chose to fuse GMCSF to the catalytic and translocation domains of DT (DT388; Ref.8 ). The DT388GMCSF molecule was cytotoxic in vitro to chemotherapy-resistant cell lines and therapy-refractory AML patient progenitors but was nontoxic to normal human myeloid progenitors (9, 10, 11, 12) . Dramatic antileukemic efficacy was observed in vivo administering DT388GMCSF to severe combined immunodeficient mice bearing human leukemia (13) . On the basis of these results, we manufactured DT388GMCSF under good manufacturing practice and obtained an IND (BB no. 8153) to perform a Phase I dose-escalation trial in patients with relapsed or refractory AML. This report describes the results of that study.


   PATIENTS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Eligibility criteria for patient entry into the study included histological bone marrow evidence for AML and age >=18 years old. Patients were required to have relapsed or refractory leukemia, a Zubrod performance status of <=2, to have fully recovered from toxicities of prior chemotherapy or radiation therapy, and to have a life expectancy of >=3 months. Eligible patients had a bilirubin <=1.5 mg/dl; transaminases <=5 x upper limit of normal, creatinine <=1.5 mg/dl; forced expiratory volume (FEV1) >=70% normal; cardiac ejection fraction >=50% normal; had no serious concurrent medical problems, uncontrolled infections, central nervous system leukemia, myocardial infarctions in the last 6 months, or history of severe penicillin allergy; and were not pregnant. Written informed consent was obtained from each patient before entry into the study.

DT388GMCSF was produced under good manufacturing practice and aliquoted in vials containing 1 ml of PBS at 1.5 mg/ml and stored at -80°C (14) . Before treatment, vials were thawed at room temperature, and appropriate amounts of drug aliquoted in a laminar flow hood for individual daily doses in sterile Eppendorf tubes and were refrozen at -80°C. Each day of treatment, a single dose was rethawed in the laminar flow hood and diluted aseptically in 1 ml of normal saline or 3% saline. A 1-h incubation at room temperature with 3% saline was used after patient 28 to reduce protein aggregates. After premedications with acetaminophen, diphenhydramine, and corticosteroids, the drug was administered as a 15-min infusion through a rapidly flowing i.v. line. Treatments were repeated daily for up to 5 days. Patients could be retreated with Federal Drug Administration approval if they had no unresolved toxicities.

Patients were monitored in-hospital for 2 weeks for toxicities. The National Cancer Institute Common Toxicity Criteria scale was used. Vital signs were measured posttherapy every 15 min for 1 h, every hour for 8 h, and then every 4 h for 7–10 days. Physical exams were done daily throughout the treatment period and for at least 1 additional week. Blood counts, blood chemistries, and urinalysis were done daily during treatment. Drug pharmacokinetics were measured with blood sampling on each treatment day. A previously described bioassay was used to quantitate circulating DT388GMCSF with an assay limit of 0.3 ng/ml (15) . Circulating cytokines (IL-1ß, IL-6, IL-8, IL-12, IL-18, macrophage inflammatory protein 1{alpha}, IFN{gamma}, and TNF{alpha}) were measured on the blood samples obtained for pharmacokinetics using enzyme immunoassays (R&D Systems, Minneapolis, MN; or MBL, Nogoya, Japan) following the directions of the manufacturers. Humoral immune response to DT388GMCSF was measured on serum that was obtained pretreatment, day 14, day 30, and day 60 by both a sandwich enzyme immunoassay and cytotoxicity neutralization assay following the methods we have reported previously (16) . Clinical response was assessed by blood counts and differentials, exams, and bone marrow aspirate and biopsies on days 12 and 30 and as indicated. A patient was considered in complete remission if there were no circulating blast, no extramedullary leukemia, the marrow blast percentage was <5%, and there was reconstitution of normal hematopoiesis with normal peripheral hemoglobin, platelet count, and neutrophil count without the need for transfusions. A partial remission occurred with the same conditions except for a lack of recovery of normal hematopoeisis.

Patients were treated at one of six dose levels (1, 2, 3, 4, 4.5, or 5 µg/kg/day for 5 days). Three to six patients were treated at each dose level to establish the MTD. Additional patients were added in some cases to better define the toxicity at that dose level. The MTD was defined as the highest dose level at which zero or one patient, among at least six patients, had DLT. DLT was defined as a drug-related >= grade 4 nonhematological toxicity or drug-related grade 4 hematological toxicity of >28 days duration. Transient asymptomatic (<2 weeks) grade 4 elevations of transaminases, CPK, or decreases in serum calcium were not considered DLTs on this study.

The cell cytotoxicity assay used the HepG2 hepatocellular carcinoma cell line and was obtained from the American Type Culture Collection (Manassas, VA) in MEM containing 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, 2 mM L-glutamine, Earle’s balanced salt solution with 1.5 g/liter sodium bicarbonate and 10% fetal bovine serum (Life Technologies, Inc., Grand Island, NY). Cells were trypsinized and aliquoted at 104 cells/well in Costar 96-well flat-bottomed tissue culture plates in 150 µl of medium containing 12 different concentrations of DT388GMCSF or DAB389EGF (a gift from Ligand Pharmaceuticals, Inc, San Diego, CA; Ref. 17 ), and were incubated at 37°C 5% CO2 for 48 h. Fifty µl of medium with 1 µCi [3H]thymidine (NEN DuPont, Wilmington, DE) was then added, and, after 18 h, media was removed and cells washed three times with serum-free media, solubilized with 50 µl of 2 M NaOH, neutralized with 50 µl of 2 M HCL, harvested onto glass fiber mats with a Skatron Cell Harvestor (Skatron Instruments, Lier, Norway), and counted on a Betaplate reader gated for 3H. The calculated IC50s were the concentrations of toxin that inhibited thymidine incorporation by 50% compared with control wells.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Patients.
Thirty-one patients were treated for a total of 39 courses (8 patients received a second course). The mean age was 54 years (range, 12–84), and there were 13 males and 18 females (Tables 1Citation and 2Citation ). Although the eligibility criteria stipulated age >=18 years, one child was allowed under a Federal Drug Administration-approved exemption. Four patients were in first relapse, 2 patients were in second relapse, and 25 patients had refractory AML. Six patients had undergone autologous bone marrow transplants, 4 had previously received allogeneic bone marrow transplants, and 21 had not received transplants. The cytogenetics were poor risk in 15 patients, intermediate risk in 8 patients, and good risk in 1 patient. In seven patients, cytogenetics had not been performed. Prior myelodysplasia had been present in 5 of the 31 patients.


View this table:
[in this window]
[in a new window]
  		Table 1 Clinical characteristics of DT388GMCSF-treated AML patients

 

View this table:
[in this window]
[in a new window]
  		Table 2 Summary of clinical characteristics of DT388GMCSF-treated AML patients

 
Toxicities.
The DLT for this dose/schedule of DT388GMCSF was liver injury. Eight patients were treated at the 4.5–5-µg/kg/day dose level, and two of these patients had severe hepatic toxicity. The dose was reduced after patient 24, although there were no DLTs, to more safely assess the effects of modified prophylaxis (rofecoxib and anti-TNF-{alpha} antibody) on the incidence and severity of toxicities. Patient 28 developed liver failure and died 1 week after treatment. This was coincident with florid leukemic progression. Necropsy showed centrilobular hepatic necrosis. Patient 31 developed transient hepatic encephalopathy with elevated ammonia levels 4 days after therapy. The liver dysfunction resolved, but the patient developed renal failure contributed to by aminoglycosides and amphotericin. Without dialysis, the patient died 1 week later. Transient elevations in AST were seen in most patients (Tables 3Citation and 4Citation ). Furthermore, the peak AST level correlated with the dose (P = 0.002; Fig. 1ACitation ) and peak DT388GMCSF level (P = 0.0002; Fig. 1BCitation ). The AST rose disproportionately relative to ALT and GGT. Steroids, calcium channel blocker, and antibody to TNF{alpha} did not influence this toxicity. The mechanism for the liver injury is unknown. As shown in Fig. 2Citation , DT388GMCSF did not damage a hepatic cell line. DT388GMCSF may indirectly injure hepatocytes by causing inflammatory cytokine release from liver Kupffer cells, which are known to have GM-CSF receptors. No liver biopsies have been performed in DT388GMCSF-treated patients, but elevated circulating levels of two inflammatory cytokines, IL-8 and IL-18, have been observed (Table 5)Citation . There was a significant positive association of IL-18 levels with AST levels (P = 0.05; Table 6Citation ). The elevations of IL-18 occurred earlier (by day 2) than the elevations of IL-8 (day 4–8; data not shown).


View this table:
[in this window]
[in a new window]
  		Table 3 Dose level and drug-related toxic effects of DT388GMCSF in AML patientsa

 

View this table:
[in this window]
[in a new window]
  		Table 4 Relationship of grade 3–5 DT388GMCSF-related toxicities and dosea

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 1. Plot of peak AST versus dose (A) and versus peak DT388GMCSF concentration (B). Patient 28 values are not displayed.

 


View larger version (22K):
[in this window]
[in a new window]
  		Fig. 2. DT fusion protein inhibition of thymidine incorporation by the HepG2 hepatocellular carcinoma cell line. Experiments were performed as described in "Patients and Methods." {blacksquare}, DT388GMCSF; •, DAB389EGF. IC50 was >3000 pM for DT388GMCSF and >59 pM for DAB389EGF.

 

View this table:
[in this window]
[in a new window]
  		Table 5 Serum cytokine levels in DT388GMCSF-treated AML patientsa

 

View this table:
[in this window]
[in a new window]
  		Table 6 Spearman rank correlations between selected parameters: n, correlation (r), Pa

 
Other drug-related side effects include fever, chills, hypoxemia, and transient hypotension postinfusion. These were rare with corticosteroid prophylaxis beginning with patient 10. A transient asymptomatic sinus bradycardia occurred in some patients that was responsive to oral theophyllines. Echocardiograms during and after treatment did not show reduced cardiac function. There were no cardiac enzyme elevations (CPK-MB fractions) and no evidence of heart block by electrocardiography. Asymptomatic, transient hypocalcemia occurred between days 4 and 10. The incidence of hypocalcemia was dose dependent. Neither neurological nor muscular abnormalities were observed. When measured, the vitamin D levels were normal and parathyroid hormone was slightly increased. Serum calcium values of <7 mg/dl were treated with i.v. calcium gluconate. Serum calciums were not corrected for the serum albumins. Transient CPK and lactate dehydrogenase elevations were observed in most patients and paralleled the changes in AST. However, there were no signs of muscle injury or RBC injury measured by serum aldolase and haptoglobin or peripheral smear. VLS with the combination of edema, weight gain, hypoxia, hypotension, and hypoalbuminemia was noted only in patients 9 and 11. Patient 9 had not been receiving thyroid medications for 1 week, and the symptoms resolved with diuresis and reinstitution of thyroxine. Patient 11 had fluid overload combined with corticosteroids that also resolved with diuresis. The other patients had signs of the components of VLS with weight gain and/or hypoalbuminemia, but there was no associated edema, hypoxemia, or hypotension. The incidence and frequency of toxicities to DT388GMCSF are shown in Tables 3Citation and 4Citation .

On the basis of the occurrence of grade 4 and 5 liver toxicities in patients 31 and 28, respectively, we determined the MTD to be 4 µg/kg/day, and nine patients have been treated at that dose to date without DLT.

Pharmacokinetics.
Pharmacokinetic data were obtained for the first infusion of each course on all 31 patients and for the first and last infusion on 5 patients. The peak DT388GMCSF serum level occurred at 2 min postinfusion, and the concentration decreased over time exponentially with a t1/2 of ~30 min (Fig. 3)Citation . The peak fusion protein concentration was not significantly correlated with the dose (P = 0.53; Fig. 4BCitation ) but was correlated with the pretreatment antibody titer (P = 0.0001; Table 7Citation ; Fig. 4ACitation ; and see "Immune Response"). Interestingly, in the five patients for whom data were available, the peak DT388GMCSF concentrations were higher on day 5 than on day 1.



View larger version (11K):
[in this window]
[in a new window]
  		Fig. 3. Serum levels in patient 15 after first infusion. Assay was performed as described in "Patients and Methods."

 


View larger version (21K):
[in this window]
[in a new window]
  		Fig. 4. Plot of pretreatment anti-DT388GMCSF serum levels versus peak serum DT388GMCSF level (A) and dose versus peak serum DT388GMCSF level (B). Fusion protein and antibody concentrations were determined as described in "Patients and Methods."

 

View this table:
[in this window]
[in a new window]
  		Table 7 Summary of antibody titers and peak serum DT388GMCSF levelsa

 
Immune Response.
We do not have a vaccination history for the 31 patients in the trial. However, most patients likely received their full immunization against DT in childhood. The EIA showed that 28 (90%) of 31 were positive (i.e., had circulating anti-DT388GMCSF antibodies) in concentrations ranging from 0.2 to 9.4 µg/ml with a median of 1.85 µg/ml (Table 7)Citation . Patients with low pretreatment antibody titers were more likely to have measurable peak circulating DT388GMCSF. The median and range of antibody for those with undetectable peak fusion protein during the first course were 2.5 µg/ml (1.1–9.4 µg/ml; n = 15), and the same antibody levels for those with measurable peak fusion protein were 0.6 µg/ml (0–3.7 µg/ml; n = 16). The difference was highly significant (P < 0.001). Only 2 of 11 patients with EIA antibody concentration above 2.2 µg/ml had detectable peak DT388GMCSF compared with 14 of 20 with EIA antibody concentrations of <2.2 µg/ml.

After 15–60 days, 21 of 25 evaluable patients had increased antibody titers ranging from 0.2 to 6613 µg/ml (Table 7)Citation . One patient had no change in antibody titer and three patients had decreased antibody titers. Of the three patients with no humoral immune response to DT388GMCSF, one patient had received two prior allogeneic bone marrow grafts, one patient had undergone a prior autologous bone marrow transplant, and the last patient was heavily pretreated with fludarabine.

Clinical Response.
Three clinical remissions were observed (Table 8)Citation . Six of the 31 patients had relapsed disease. The three responses were seen in this group. No responses were seen in the refractory patients. Patient 22 was a 72-year-old female who developed AML in April 1996. She had normal cytogenetics and received idarubicin plus cytarabine (3 + 7), achieving a complete remission. She had no consolidation therapy, relapsed in January 2000 and received salvage therapy consisting of topotecan and high-dose cytarabine. However, she was refractory, and bone marrow biopsy on March 8, 2000, showed 28% blasts confirmed by flow cytometry (Fig. 5A)Citation . She received a 5-day course of DT388GMCSF at 5 µg/kg/day complicated only by asymptomatic and transient transaminasemia, elevated CPK, and hypocalcemia from April 10 to April 14, 2000. Before therapy, she had an ANC of 280/µl, a platelet count of 64,000/µl, and no circulating blasts. One and 2 months posttherapy, her bone marrow showed 1–3% blasts by morphology and flow cytometry (Fig. 5B)Citation . She had recovery of platelets by day 60 to 158,000/µl but continued to be neutropenic (ANC of 279/µl). She was active spending most days out of the home and did not require antibiotics. By August 17, 2000, she had normalization of counts with an ANC of 1,320/µl, a platelet count of 238,000/µl, and a hemoglobin of 12.0 g/dl, and did not require transfusions or antibiotics. Repeat bone marrow exam on November 15, 2000, showed no morphological evidence of increased blasts, but there were 8% blasts by flow cytometry. Her blood counts remained normal with an ANC of 1,600/µl, a hemoglobin of 14.2 g/dl, and a platelet count of 180,000/µl. By March 29, 2001, she had a recurrence of pancytopenia (ANC of 420/µl, platelet count of 76,000/µl, and hemoglobin of 12.8 g/dl). There were no circulating blasts, but the bone marrow examination showed 8% blasts by morphology and 12% blasts by flow cytometry. She received a second course of DT388GMCSF at 5 µg/kg/day for 5 days, and the day-12 bone marrow showed disappearance of the blasts by morphology and flow cytometry. By day 17 after the second course, her ANC was 1,000/µl However, she remained thrombopenic (platelet count of 7/µl)and anemic (hemoglobin of 7.1 g/dl). On day 21, she developed a pneumonia, confirmed by chest X-ray, but declined aggressive management and died on day 24 posttherapy.


View this table:
[in this window]
[in a new window]
  		Table 8 Summary of effects of DT388GMCSF on bone marrow blasts

 


View larger version (67K):
[in this window]
[in a new window]
  		Fig. 5. Photomicrographs of H&E-stained sections of bone marrow biopsies obtained pretreatment (A) and 1-month posttreatment with DT388GMCSF (B).

 
Patient 24 was a 33-year-old female diagnosed with AML in November 1998 and induced with idarubicin plus cytarabine (3 + 7) followed by an allogeneic bone marrow transplant in June 1999. She developed bronchiolitis obliterans, requiring chronic corticosteroids, and had relapse of her AML in April 2000. Bone marrow exam showed 14% blasts. She had 300/µl circulating blasts and thrombopenia (platelet count of 23,000/µl). She received DT388GMCSF at 5 µg/kg/day for 5 days, and, again, the only side effects were transient, asymptomatic transaminasemia and hypocalcemia. Her day-30 bone marrow showed 2% blasts, but she remained pancytopenic with an ANC of 75/µl, a platelet count of 25,000/µl and a hemoglobin of 10.8 g/dl. She was asymptomatic. She received a course of granulocyte colony-stimulating factor (G-CSF) to stimulate recovery of normal myelopoiesis, however, by day 60, a repeat bone marrow showed an increase in blast percentage to 15%. She was again treated with DT388GMCSF at 5 µg/kg/day complicated only by asymptomatic and transient transaminasemia. Her marrow blasts at day 30 were 5–10%. She continued to have neutropenia and thrombopenia. She died 1 year after initiating fusion protein therapy in April 2001.

Patient 25 was a 70-year-old male diagnosed with AML in March 2000 and treated with idarubicin plus cytarabine for induction and consolidation. He relapsed in April 2000 with a bone marrow showing 15% blasts. He had circulating blasts (50/µl), thrombopenia (platelet count of 34,000/µl), and anemia (hemoglobin 8.3 g/dl). He was treated from 6/22/00 to 6/26/00 with DT388GMCSF at 3 µg/kg/day. His course was complicated by transient renal insufficiency attributed to rofecoxib and transient, asymptomatic transaminasemia, hypocalcemia, and elevated CPK. The day-12 marrow showed 1% blasts, and the day-30 marrow showed 4% blasts. However, he remained anemic and thrombopenic. He declined further fusion protein or other therapy and died from progressive disease 40 days posttherapy.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The diphtheria fusion protein DT388GMCSF unexpectedly produced liver injury characterized by transient transaminasemia and, rarely, more severe liver dysfunction. The MTD of 4 µg/kg/day for 5 days or 20 µg/kg total per course is much lower than that observed for the other systemically administered clinically active fusion proteins ONTAK, LMB–2, and BL22 (120, 120, and 135 µg/kg/total, respectively; Refs. 19 , 21 , 22 ) and resembles the low MTDs of 18 and 3 µg/kg/total DAB389EGF and erb-38, respectively (23) . Both DAB389EGF and erb-38 bound hepatocytes and produced direct liver injury (see Fig. 3Citation ). In contrast, DT388GMCSF does not directly bind or damage hepatocytes. We hypothesize that the fusion protein bound the GMCSF receptor-positive macrophages in the liver (Kupffer cells) and triggered cytokine release. We have observed extremely elevated circulating levels of IL-18 in treated patients. IL-18 is a known pro-inflammatory cytokine that can be released by stimulated Kupffer cells and can damage hepatocytes by inducing their expression of Fas, leading to Fas ligand-mediated cell death (24 , 25) . Other laboratories have shown that cyclosporin, FK506, and monoclonal anti-IL-18 antibodies can provide effective prophylaxis in vivo for IL-18-inducing liver toxins (26 , 27) . Whereas our data are consistent with the hypothesis of Kupffer cell cytokine-induced liver injury, the cause of the DT388GMCSF hepatotoxicity is not identified definitively.

The humoral immune response to DT fusion proteins clearly affected circulating levels of DT388GMCSF and likely influenced clinical benefit at the low doses used in this study. Approaches to circumvent the immune response are to carefully select patients with low pretreatment antibody titers or to alter the schedule and use fewer but higher doses. Another approach is to engineer and develop other targeted toxins that can intoxicate malignant myeloid cells. An antibody to CD33 has been humanized and conjugated to recombinant gelonin, a plant ribosome-inactivating protein (28) . Human proteins such as eosinophil-derived neurotoxin, a member of the RNase family, may be engineered to target myeloblasts (29) . This toxin, combined with a human-derived ligand peptide, should be less immunogenic in patients.

We observed clinical activity with DT388GMCSF in highly chemoresistant AML patients. This observation confirms the antileukemic activity observed with this drug in tissue culture and animal models (10, 11, 12, 13) . Similar fusion proteins (DAB389IL-2, Tf-CRM107, LMB-2, and LMB-7) directed to other receptors have yielded 30–80% response rates in cutaneous T-cell lymphoma, high-grade gliomas, and hairy cell leukemia (19, 20, 21, 22) . The observed response rate of 10% is significantly lower than with these other fusion proteins. There are several possible explanations for this difference. First, DT388GMCSF may be less active in patients than are the other proteins. The preclinical data does not support this hypothesis. In tissue culture, leukemic progenitors were killed with picomolar concentrations of drug (9, 10, 11, 12) . In vivo, long-term remissions were produced with DT388GMCSF (13) . These results compare favorably with the other clinically efficacious fusion proteins. A second hypothesis is that most patients were treated at suboptimal doses, and very few patients received therapeutic amounts of DT388GMCSF. Only 18 of 31 patients received doses at or above the MTD (4 to 5 µg/kg/day). A slow interpatient dose escalation was done because of the novel nature of this drug and the comorbidities and non-drug-related toxicities that are common in these highly pretreated leukemic patients. A third hypothesis is that the early occurrence of DLT limited the dose escalation and prevented administration of adequate dose levels to achieve a higher response rate. The liver toxicity precluded dose escalation, and reducing the liver toxicity should permit dose escalation. A fourth factor that likely contributed to the low response rate was the presence of pretreatment anti-DT antibodies in many of the patients. Whereas the influence of anti-DT antibodies is less pronounced when higher doses of DT fusion proteins are given (19) , when only 4–5 µg/kg fusion protein can be administered, the antibodies likely reduce blast exposure to drug. We failed to observe circulating drug in most patients with high anti-DT antibody titers. Fifth, there may be significant patient-to-patient variations in sensitivity to DT388GMCSF that were not detected with the previously used colony-forming assay (AML-CFC; Refs. 9, 10, 11, 12 ). In support of this hypothesis, we have found dramatic differences in patient leukemic blast sensitivity to DT388GMCSF using a 3-day proliferation assay.4 However, patient blast GM-CSF receptor content and DT388GMCSF sensitivity was not measured prospectively in our study patients. Finally, the patients treated on this study, in most instances, had very advanced disease. In only 12 of 39 courses were patients treated who had <30% marrow blasts. Patients with extensive tumor burden may be less sensitive to biologicals such as DT388GMCSF, particularly at the low dose levels used in this study. All of the responses observed occurred among the 12 patients with low marrow-blast percentage.

We are committed to discovering approaches to improve the preliminary response rate observed in the Phase I study. First, we are investigating the molecular mechanism for the liver toxicity and looking for methods of prophylaxis that will protect the liver without modifying the antileukemic efficacy. We are testing oral glycine prophylaxis to block Kupffer cell activation and liver injury from DT388GMCSF (30). The selective glycine inhibition of liver macrophage should not impair the antileukemic activity of DT388GMCSF. Second, we are evaluating prognostic factors that may identify a patient category more likely to respond, including low pretreatment anti-DT antibody titer, high sensitivity of pretreatment blasts to DT388GMCSF, and low pretreatment leukemic burden. Third, we will give the fusion protein on a twice-weekly-for-2-weeks schedule as has been used successfully for the Pseudomonas exotoxin fusion proteins (i.e., LMB-2 and BL22). Such a schedule may permit higher individual doses to be given and yield better blast saturation both in the blood and marrow and other extravascular sites.

Although multiple issues need to be addressed to improve the therapeutic index of the DT388GMCSF fusion protein for therapy of myeloid malignancies, the preliminary results are encouraging and suggest that additional preclinical and clinical development is warranted.


   ACKNOWLEDGMENTS
 
We thank Drs. Samer Renno, Itzvan Molnar, and Andrew Mone for their assistance in developing some of the in vitro cytokine assays, patient serum DT388GMCSF assays, and patient serum cytokine assays used in this study. We also thank Jason Ramage and Jennifer Black for excellent technical assistance, Cynthia Patrick for clinical protocol nursing support, Dr. Mark Willingham for assistance with photomicroscopy, and Dr. Charles McCall for advice and guidance during this study. We also thank Dr. Dianna Howard at the University of Kentucky Medical Center for the care of two of the patients on protocol.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by the Leukemia and Lymphoma Society (LSA6114-99), NIH (1R01CA76178, 1R21CA90550, and M01RR07122), and the Wake Forest University School of Medicine. Back

2 To whom requests for reprints should be addressed, at Hanes 4046, Wake Forest University School of Medicine, Medical Center Drive, Winston-Salem, NC 27157. Phone: (336) 716-3313; Fax: (336) 716-0255; E-mail: afrankel{at}wfubmc.edu Back

3 The abbreviations used are: AML, acute myeloid leukemia; GMCSF, granulocyte-macrophage colony-stimulating factor; MTD, maximal tolerated dose; DLT, dose-limiting toxicity; TNF, tumor necrosis factor; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DT, diphtheria toxin; CPK, creatine phosphokinase; VLS, vascular leak syndrome; ANC, absolute neutrophil count; IND, investigational new drug; GGT, gamma-glutamyl aminotransferase; EIA, enzyme immunoassay. Back

4 A. E. Frankel, unpublished observations. Back

Received 9/ 8/01; revised 1/23/02; accepted 1/30/02.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 PATIENTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Greenlee R. T., Hill-Harmon M. B., Murray T., Thun M. Cancer statistics, 2001. CA Cancer J. Clin., 51: 15-36, 2001.[Abstract/Free Full Text]
  2. Bennett J. M., Young M. L., Andersen J. W., Casssileth P. A., Tallman M. S., Paietta E., Wiernik P. H., Rowe J. M. Long-term survival in acute myeloid leukemia: the Eastern Cooperative Oncology Group Experience. Cancer (Phila.), 80 (Suppl. 11): 2205-2209, 1997.[CrossRef][Medline]
  3. Estey E. H. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia (Baltimore), 14: 476-479, 2000.[CrossRef][Medline]
  4. Lowenberg B., Sonneveld P. Resistance to chemotherapy in acute leukemia. Curr. Opin. Oncol., 10: 31-35, 1998.[Medline]
  5. Sauerbrey A., Zintl F., Hermann J., Volm M. Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL). Anticancer Res., 18: 1231-1236, 1998.[Medline]
  6. List A., Spier C., Grogan T., Johnson C., Roe D., Greer J., Wolff S., Broxterman H., Scheffer G., Scheper R., Dalton W. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood, 87: 2464-2469, 1996.[Abstract/Free Full Text]
  7. Frankel A. E., Powell B. L., Vallera D. A., Neville D. A. Chimeric fusion proteins (diphtheria toxin-based). Curr. Opin. Investig. Drugs, 2: 1294-1301, 2001.[Medline]
  8. Kreitman R. J., Pastan I. Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood, 90: 252-259, 1997.[Abstract/Free Full Text]
  9. Frankel A. E., Hall P., Burbage C., Vesely J., Willingham M. C., Bhalla K., Kreitman R. J. Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin-granulocyte-macrophage colony stimulating factor (GMCSF) fusion protein. Blood, 90: 3654-3661, 1997.[Abstract/Free Full Text]
  10. Hogge D. E., Willman C. L., Kreitman R. J., Berger M., McLain C., Hall P. D., Kopecky K. J., Tagge E. P., Frankel A. E. Malignant progenitors from patients with acute myelogenous leukemia are sensitive to a diphtheria toxin-granulocyte-macrophage colony stimulating factor (GMCSF) fusion protein. Blood, 92: 589-595, 1998.[Abstract/Free Full Text]
  11. Feuring-Buske M., Frankel A. E., Gerhard B., Hogge D. Cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony stimulating factor (DT388-GMCSF) fusion protein for acute myelogenous leukemia (AML) stem cells. Exp. Hematol., 28: 1390-1400, 2000.[CrossRef][Medline]
  12. Frankel A. E., Lilly M., Kreitman R. J., Hogge D., Beran M., Freedman M. H., Emanuel P. D., McLain C., Hall P., Tagge E. P., Berger M., Eaves C. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Blood, 92: 4279-4286, 1998.[Abstract/Free Full Text]
  13. Hall P. D., Kreitman R. J., Willingham M. C., Tagge E. P., Frankel A. E. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor prolongs the survival of scid mice bearing human acute myelogenous leukemia. Leukemia (Baltimore), 13: 629-633, 1999.[CrossRef][Medline]
  14. Frankel A. E., Ramage J., Latimer A., Feely T., Delatte S., Hall P., Tagge E., Kreitman R. J., Willingham M. C. High level synthesis and maximal purification of the recombinant diphtheria fusion toxin DTGM for Phase I clinical trials. Protein Expr. Purif., 16: 190-201, 1999.[CrossRef][Medline]
  15. Hotchkiss C. E., Hall P. D., Cline J. M., Willingham M. C., Kreitman R. J., Gardin J., Latimer A., Ramage J., Feely T., Frankel A. E. Toxicology and pharmacokinetics of DTGM, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human granulocyte-macrophage colony stimulating factor (GM-CSF), in cynomolgus monkeys. Toxicol. Appl. Pharmacol., 158: 152-160, 1999.[CrossRef][Medline]
  16. Hall P. D., Virella G., Beckham W., Frankel A. E. Adult AML patients treated with DTGM diphtheria fusion toxin do not have neutralizing antibodies before or after the first treatment course. Clin. Immunol., 100: 191-197, 2001.[CrossRef][Medline]
  17. Shaw J. P., Akiyoshi D. E., Arrigo D. A., Rhoad A. E., Sullivan B., Thomas J., Genbauffe F. S., Bacha P., Nichols J. C. Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins. J. Biol. Chem., 266: 13449-13455, 1991.[Abstract/Free Full Text]
  18. Olsen E., Duvic M., Frankel A., Kim Y., Martin A., Vonderheid E., Jegasothy B., Wood G., Gordon M., Heald P., Oseroff A., Pinter-Brown L., Bowen G., Kuzel T., Fivenson D., Foss F., Glode M., Molina A., Knobler E., Stewart S., Cooper K., Stevens S., Craig F., Reuben J., Bacha P., Nichols J. Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. Oncol., 19: 376-388, 2001.[Abstract/Free Full Text]
  19. Laske D. W., Youle R. J., Oldfield E. H. Tumor regression with regional distribution of the targeted toxin Tf-CRM107 in patients with malignant brain tumors. Nat. Med., 3: 1362-1368, 1997.[CrossRef][Medline]
  20. Kreitman R. J., Wilson W. H., White J. D., Stetler-Stevenson M., Jaffe E. S., Giardina S., Waldman T. A., Pastan I. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J. Clin. Oncol., 18: 1622-1636, 2000.[Abstract/Free Full Text]
  21. Kreitman R. J., Wilson W. H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D. J., Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med., 345: 241-247, 2001.[Abstract/Free Full Text]
  22. Pai-Scherf L. H., Villa J., Pearson D., Watson T., Liu E., Willingham M. C., Pastan I. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Clin. Cancer Res., 5: 2311-2315, 1999.[Abstract/Free Full Text]
  23. Nakanishi K., Yoshimoto T., Tsutsui H., Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu. Rev. Immunol., 19: 423-474, 2001.[CrossRef][Medline]
  24. Tsutsui H., Matsui K., Okamura H., Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol. Rev., 174: 192-209, 2000.[CrossRef][Medline]
  25. Dinarello C. A. Interleukin-18, a proinflammatory cytokine. Eur. Cytokine Netw., 11: 483-486, 2000.[Medline]
  26. Kuinose M., Iwagaki H., Morimoto Y., Kohka H., Kobashi K., Sadamori H., Inagaki M., Urushihara N., Yagi T., Tanaka N. Calcineurin antagonists inhibit interferon-{gamma} production by downregulation of interleukin-18 in human mixed lymphocyte reactions. Acta Med. Okayama, 54: 201-209, 2000.
  27. Pagliaro L. C., Liu B., Munker R., Andreef M., Freireich E. J., Scheinberg D. A., Rosenblum M. G. Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity. Clin. Cancer Res., 4: 1971-1976, 1998.[Abstract]
  28. Newton D. L., Nicholls P. J., Rybak S. M., Youle R. J. Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv. J. Biol. Chem., 269: 26739-26745, 1994.[Abstract/Free Full Text]
  29. Schemmer P., Golling M., Kraus T., Mayatepek E., Herfarth C., Klar E. Glycine reduces reperfusion injury in human liver transplantation: our first patients. Transplant. Proc., 33: 3750-3752, 2001.[CrossRef][Medline]



This article has been cited by other articles:


Home page
 BloodHome page
U. Testa, R. Riccioni, M. Biffoni, D. Diverio, F. Lo-Coco, R. Foa, C. Peschle, and A. E. Frankel
Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression
Blood, October 1, 2005; 106(7): 2527 - 2529.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. M. Westcott, R. J. Abi-Habib, K. A. Cohen, M. C. Willingham, S. Liu, T. H. Bugge, S. H. Leppla, and A. E. Frankel
Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells
Mol. Cancer Ther., December 1, 2004; 3(12): 1681 - 1689.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. J. Kreitman
Confirmation and prevention of targeted toxicity by a recombinant fusion toxin
Mol. Cancer Ther., December 1, 2004; 3(12): 1691 - 1692.
[Full Text] [PDF]

Home page
 BloodHome page
R. J. Abi-Habib, S. Liu, T. H. Bugge, S. H. Leppla, and A. E. Frankel
A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts
Blood, October 1, 2004; 104(7): 2143 - 2148.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. K. Tur, M. Huhn, T. Thepen, M. Stocker, R. Krohn, S. Vogel, E. Jost, R. Osieka, J. G. van de Winkel, R. Fischer, et al.
Recombinant CD64-Specific Single Chain Immunotoxin Exhibits Specific Cytotoxicity against Acute Myeloid Leukemia Cells
Cancer Res., December 1, 2003; 63(23): 8414 - 8419.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Thorburn, A. E. Frankel, and A. Thorburn
Apoptosis by Leukemia Cell-targeted Diphtheria Toxin Occurs via Receptor-independent Activation of Fas-associated Death Domain Protein
Clin. Cancer Res., February 1, 2003; 9(2): 861 - 865.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Liu, H. Aaronson, D. J. Mitola, S. H. Leppla, and T. H. Bugge
Potent antitumor activity of a urokinase-activated engineered anthrax toxin
PNAS, January 21, 2003; 100(2): 657 - 662.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian
Acute Myeloid Leukemia
Hematology, January 1, 2002; 2002(1): 73 - 110.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frankel, A. E.
Right arrow Articles by Kreitman, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frankel, A. E.
Right arrow Articles by Kreitman, R. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online